Latebreakers: Associations have mixed reactions to behind-the-counter drugs
FDA's behind-the-counter drugs proposal draws mixed reactions from pharmacy associations
A spokeswoman for the Consumer Healthcare Products Association stated, "CHPA and its member companies believe that the current two-class system is the best system for the American consumer and are open to discussions about expanding access."
An NACDS spokesman said, "This is an issue that the association's governance will be considering. The FDA is in the developmental stages on the issue, so it is not possible at this time to react to a specific proposal. We look forward to contributing to the discussion as it moves forward, pending the establishment of an NACDS position. This issue has highlighted the important role of the pharmacist in the healthcare system, which is positive." The FDA announced a Nov. 12 hearing to discuss its proposal. The announcement was published in the Oct. 4 Federal Register.
